1.810USD-5.97%Mkt Cap: 244.23M USDP/E: —Last update: 2026-06-01
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeu…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap244.23M USD
Enterprise Value123.86M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-101.69M USD
Revenue/Share—
Last Price1.810 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees43
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.53
PEG—
EV/EBITDA-1.42
EV/Revenue—
P/S—
P/B1.69
EPS (TTM)-1.49
EPS (Forward)-0.54
52W Range
0.404062% of range2.660
52W High2.660 USD
52W Low0.4040 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-391.42%
ROA-172.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-84.14M USD
CapEx (TTM)212.00K USD
FCF Margin—
FCF Yield-17.72%
Net Debt-131.81M USD
Net Debt/EBITDA1.51
Balance Sheet
Debt/Equity0.38
Current Ratio7.21
Quick Ratio6.95
Book Value/Sh1.125 USD
Cash/Share1.043 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.600 USD
Target Range4.000 USD – 6.000 USD
# Analysts5
Ownership
Shares Out.134.56M
Float107.02M
Insiders0.92%
Institutions78.77%
Short Interest
Short Ratio1.4d
Short % Float1.14%
Short % Out.1.03%
Shares Short1.38M
Short (prev mo.)2.05M
Technical
SMA 501.892 (-4.3%)
SMA 2001.634 (+10.8%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)986.89K
Avg Vol (10d)1.19M
Technical Indicators
RSI (14)50.1
MACD0.0240
MACD Signal0.0348
MACD Hist.-0.0108
BB Upper2.154 USD
BB Middle1.969 USD
BB Lower1.784 USD
BB Width18.80%
ATR (14)0.1316 USD
Vol Ratio (20d)0.37x